MA50013A - Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton - Google Patents

Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton

Info

Publication number: MA50013A
Authority: MA; Morocco
Prior art keywords: benzoazpine; tyrosine kinase; kinase inhibitors; bruton tyrosine; analogues used
Prior art date: 2017-04-14

Application number

MA050013A

Other languages

English (en)

Other versions

MA50013B1 (fr

Inventor

Brian T Hopkins

Joseph P Lyssikatos

Bin Ma

Isaac Marx

Daniel B Patience

Matthew Peterson

Robin Prince

Fengmei Zheng

Original Assignee

Biogen Ma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-14

Filing date

2018-04-13

Publication date

2020-07-08

2018-04-13 Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc

2020-07-08 Publication of MA50013A publication Critical patent/MA50013A/fr

2024-05-31 Publication of MA50013B1 publication Critical patent/MA50013B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA50013A 2017-04-14 2018-04-13 Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton MA50013B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762485745P	2017-04-14	2017-04-14
PCT/US2018/027415 WO2018191577A1 (fr)	2017-04-14	2018-04-13	Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton

Publications (2)

Publication Number	Publication Date
MA50013A true MA50013A (fr)	2020-07-08
MA50013B1 MA50013B1 (fr)	2024-05-31

Family

ID=62092333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA50013A MA50013B1 (fr)	2017-04-14	2018-04-13	Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton

Country Status (37)

Country	Link
US (5)	US10227341B2 (fr)
EP (2)	EP3609886B1 (fr)
JP (3)	JP7145874B2 (fr)
KR (3)	KR20250140646A (fr)
CN (2)	CN117567453A (fr)
AR (2)	AR111594A1 (fr)
AU (3)	AU2018253209B2 (fr)
CA (1)	CA3058774A1 (fr)
CL (1)	CL2019002900A1 (fr)
CO (1)	CO2019012571A2 (fr)
CR (2)	CR20190517A (fr)
DK (1)	DK3609886T3 (fr)
EA (1)	EA201992354A1 (fr)
ES (1)	ES2975769T3 (fr)
FI (1)	FI3609886T3 (fr)
HR (1)	HRP20240361T1 (fr)
HU (1)	HUE066253T2 (fr)
IL (3)	IL316713A (fr)
JO (1)	JOP20190233A1 (fr)
LT (1)	LT3609886T (fr)
MA (1)	MA50013B1 (fr)
MD (1)	MD3609886T2 (fr)
MX (1)	MX2023000812A (fr)
NZ (1)	NZ757929A (fr)
PE (2)	PE20240930A1 (fr)
PH (1)	PH12019502334A1 (fr)
PL (1)	PL3609886T3 (fr)
PT (1)	PT3609886T (fr)
RS (1)	RS65386B1 (fr)
SA (1)	SA519410292B1 (fr)
SG (1)	SG11201909224QA (fr)
SI (1)	SI3609886T1 (fr)
SM (1)	SMT202400166T1 (fr)
TW (2)	TWI846229B (fr)
UA (1)	UA127347C2 (fr)
WO (1)	WO2018191577A1 (fr)
ZA (1)	ZA202306172B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201604595VA (en)	2013-12-11	2016-07-28	Biogen Ma Inc	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JOP20190233A1 (ar)	2017-04-14	2019-10-02	Biogen Ma Inc	نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MA53914A (fr) *	2018-10-15	2021-08-25	Biogen Ma Inc	Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton
US12240838B2 (en)	2019-05-15	2025-03-04	Biogen Ma Inc.	Inhibiting agents for Bruton's tyrosine kinase
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
US20240216330A1 (en) *	2021-04-02	2024-07-04	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
EP4429770A1 (fr)	2021-11-10	2024-09-18	Biogen MA Inc.	Inhibiteurs de btk
EP4457225A4 (fr)	2021-12-30	2025-09-24	Beigene Switzerland Gmbh	Dégradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procédés d'utilisation
JP7805983B2 (ja)	2022-03-22	2026-01-26	アッヴィ・インコーポレイテッド	ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245578A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique
WO2024245577A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
WO2008116064A2 (fr)	2007-03-21	2008-09-25	Bristol-Myers Squibb Company	Composés hétérocycliques fusionnés utiles en tant que modulateurs de kinases
CN104119336B (zh)	2007-10-05	2016-08-24	维拉斯通股份有限公司	嘧啶取代的嘌呤衍生物
WO2009107391A1 (fr)	2008-02-27	2009-09-03	武田薬品工業株式会社	Composé contenant un cycle aromatique à 6 chaînons
SG10201510696RA (en)	2008-06-27	2016-01-28	Celgene Avilomics Res Inc	Heteroaryl compounds and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2771822C (fr) *	2009-09-04	2020-08-11	Daniel A. Erlanson	Inhibiteurs de tyrosine kinase de bruton
US8334292B1 (en)	2010-06-14	2012-12-18	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
CN106243113B (zh)	2011-07-19	2018-12-18	默沙东有限责任公司	作为btk抑制剂的选择的咪唑并吡嗪类
TWI648273B (zh) *	2013-02-15	2019-01-21	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺類（三）
US20140357636A1 (en)	2013-02-21	2014-12-04	Wayne Rothbaum	Treatment of Skeletal-Related Disorders
RU2019131017A (ru)	2013-10-21	2019-11-25	Мерк Патент Гмбх	Соединения гетероарила в качестве ингибиторов btk и их применение
SG11201604595VA (en) *	2013-12-11	2016-07-28	Biogen Ma Inc	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016057500A1 (fr) *	2014-10-06	2016-04-14	Merck Patent Gmbh	Composés hétéroaryle servant d'inhibiteurs de la btk, et leurs utilisations
JOP20190233A1 (ar) *	2017-04-14	2019-10-02	Biogen Ma Inc	نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

2017
- 2017-06-16 JO JOP/2019/0233A patent/JOP20190233A1/ar unknown
2018
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/fr active Active
- 2018-04-13 IL IL316713A patent/IL316713A/en unknown
- 2018-04-13 HR HRP20240361TT patent/HRP20240361T1/hr unknown
- 2018-04-13 MD MDE20200193T patent/MD3609886T2/ro unknown
- 2018-04-13 TW TW111149550A patent/TWI846229B/zh active
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 KR KR1020257031163A patent/KR20250140646A/ko active Pending
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/fr not_active Ceased
- 2018-04-13 PT PT187216320T patent/PT3609886T/pt unknown
- 2018-04-13 PE PE2024000228A patent/PE20240930A1/es unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active Active
- 2018-04-13 RS RS20240419A patent/RS65386B1/sr unknown
- 2018-04-13 NZ NZ757929A patent/NZ757929A/en unknown
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 ES ES18721632T patent/ES2975769T3/es active Active
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 SM SM20240166T patent/SMT202400166T1/it unknown
- 2018-04-13 KR KR1020237040706A patent/KR102862996B1/ko active Active
- 2018-04-13 IL IL294175A patent/IL294175B2/en unknown
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 HU HUE18721632A patent/HUE066253T2/hu unknown
- 2018-04-13 PL PL18721632.0T patent/PL3609886T3/pl unknown
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-04-13 SI SI201831083T patent/SI3609886T1/sl unknown
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/fr active Pending
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 CA CA3058774A patent/CA3058774A1/fr active Pending
- 2018-04-13 MA MA50013A patent/MA50013B1/fr unknown
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
2019
- 2019-04-13 CR CR20230539A patent/CR20230539A/es unknown
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP7581294B2/ja active Active
2023
- 2023-06-12 ZA ZA2023/06172A patent/ZA202306172B/en unknown
- 2023-06-15 AR ARP230101541A patent/AR129632A2/es unknown
2024
- 2024-06-20 AU AU2024204241A patent/AU2024204241A1/en active Pending
- 2024-10-30 JP JP2024190472A patent/JP7778206B2/ja active Active

Also Published As

Publication number	Publication date
JP7145874B2 (ja)	2022-10-03
CR20190517A (es)	2020-02-13
AU2022218560B2 (en)	2024-04-04
EP3609886A1 (fr)	2020-02-19
AU2018253209B2 (en)	2022-06-02
HRP20240361T1 (hr)	2024-06-07
CN110621670A (zh)	2019-12-27
TW202315870A (zh)	2023-04-16
CN117567453A (zh)	2024-02-20
AU2018253209A1 (en)	2019-10-31
ES2975769T3 (es)	2024-07-15
US20180297992A1 (en)	2018-10-18
FI3609886T3 (fi)	2024-03-26
CO2019012571A2 (es)	2020-01-17
EP4249071A3 (fr)	2024-01-24
WO2018191577A1 (fr)	2018-10-18
US20180362522A1 (en)	2018-12-20
US10227341B2 (en)	2019-03-12
US20200239459A1 (en)	2020-07-30
EP3609886B1 (fr)	2024-02-07
US10189829B2 (en)	2019-01-29
US20210340135A1 (en)	2021-11-04
TW201841909A (zh)	2018-12-01
JP7778206B2 (ja)	2025-12-01
MD3609886T2 (ro)	2024-07-31
IL316713A (en)	2024-12-01
LT3609886T (lt)	2024-04-10
SMT202400166T1 (it)	2024-07-09
PL3609886T3 (pl)	2024-05-13
IL294175A (en)	2022-08-01
HUE066253T2 (hu)	2024-07-28
PE20240930A1 (es)	2024-04-30
JP7581294B2 (ja)	2024-11-12
PT3609886T (pt)	2024-04-11
IL269933A (fr)	2019-11-28
EA201992354A1 (ru)	2020-03-10
AU2022218560A1 (en)	2022-09-15
JP2022180498A (ja)	2022-12-06
AU2024204241A1 (en)	2024-07-11
BR112019021399A2 (pt)	2020-04-28
PE20200740A1 (es)	2020-07-24
JP2025020247A (ja)	2025-02-12
CN110621670B (zh)	2023-09-15
SG11201909224QA (en)	2019-11-28
AR129632A2 (es)	2024-09-11
US11427577B2 (en)	2022-08-30
US11858926B2 (en)	2024-01-02
KR20250140646A (ko)	2025-09-25
DK3609886T3 (da)	2024-03-18
MX2023000812A (es)	2023-02-27
IL294175B2 (en)	2025-04-01
SI3609886T1 (sl)	2024-05-31
TWI790227B (zh)	2023-01-21
CL2019002900A1 (es)	2020-01-24
KR102862996B1 (ko)	2025-09-22
CA3058774A1 (fr)	2018-10-18
KR20190139926A (ko)	2019-12-18
JP2020516659A (ja)	2020-06-11
AR111594A1 (es)	2019-07-31
IL269933B (en)	2022-07-01
IL294175B1 (en)	2024-12-01
TWI846229B (zh)	2024-06-21
MA50013B1 (fr)	2024-05-31
ZA202306172B (en)	2024-11-27
JOP20190233A1 (ar)	2019-10-02
KR20230164247A (ko)	2023-12-01
RS65386B1 (sr)	2024-04-30
EP4249071A2 (fr)	2023-09-27
CR20230539A (es)	2024-04-08
US10961237B2 (en)	2021-03-30
UA127347C2 (uk)	2023-07-26
PH12019502334A1 (en)	2020-09-21
NZ757929A (en)	2025-10-31
SA519410292B1 (ar)	2023-03-12
KR102607900B1 (ko)	2023-11-29
US20230147490A1 (en)	2023-05-11

Publication	Publication Date	Title
MA50013A (fr)	2020-07-08	Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA52486A (fr)	2021-03-10	Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA47460A (fr)	2019-12-18	Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA48994A (fr)	2020-02-05	Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA54076A (fr)	2022-02-09	2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr)	2022-10-26	2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3687543A4 (fr)	2021-06-23	Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
FR25C1047I1 (fr)	2026-01-02	Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA48803A (fr)	2020-04-08	Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA45244A (fr)	2019-04-17	Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA46180A (fr)	2021-03-24	Analogues de l'amyline
MA53110A (fr)	2021-05-12	Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA46196A (fr)	2021-05-19	Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
DK3265084T3 (da)	2024-02-12	Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MX384833B (es)	2025-03-14	Inhibidores de tirosina quinasa de bruton
MA40774A (fr)	2017-08-08	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA51429A (fr)	2021-04-07	Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA49956A (fr)	2020-07-01	Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA47086A (fr)	2021-04-28	Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA41350A (fr)	2017-11-21	Synthèse d'un inhibiteur de la tyrosine kinase de bruton
MA47736A (fr)	2021-04-21	Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA49374A (fr)	2021-04-21	Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
ZA201903694B (en)	2021-04-28	Inhibitors of bruton's tyrosine kinase